Document Detail


Emerging cardiometabolic complications of androgen deprivation therapy.
MedLine Citation:
PMID:  20148744     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Prostate cancer (PCa) is the most common malignancy in men. Androgen deprivation therapy (ADT) is used in the treatment of locally advanced and metastatic PCa. Although its use has improved survival in a subset of patients, it also has negative consequences. Osteoporosis, sexual dysfunction, hot flashes and adverse changes in body composition are well-known and well-studied complications of ADT. Recent studies have also found metabolic complications in these men such as insulin resistance, diabetes and metabolic syndrome. In addition, these men might also experience higher cardiovascular mortality. Studies are needed to determine the mechanism behind these complications and to employ strategies to prevent them.
Authors:
Karen Choong; Shehzad Basaria
Related Documents :
17110904 - Scleredema adultorum of buschke: an under recognized skin complication of diabetes.
9766154 - Lipid peroxidation in type 2 diabetes: relationship with macrovascular disease?
19821754 - The assessment of glycemic variability and its impact on diabetes-related complications...
17128544 - Endocrinology update 2006.
9662044 - Upregulation of hypothalamic nitric oxide synthase gene expression in streptozotocin-in...
20530744 - Perk (eif2ak3) regulates proinsulin trafficking and quality control in the secretory pa...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The aging male : the official journal of the International Society for the Study of the Aging Male     Volume:  13     ISSN:  1473-0790     ISO Abbreviation:  Aging Male     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-02-12     Completed Date:  2010-03-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9808210     Medline TA:  Aging Male     Country:  England    
Other Details:
Languages:  eng     Pagination:  1-9     Citation Subset:  IM    
Affiliation:
Section of Endocrinology, Diabetes, and Nutrition, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts 02118, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Androgen Antagonists / adverse effects*,  therapeutic use
Body Composition
Cardiovascular Diseases / chemically induced,  etiology*
Gonadotropin-Releasing Hormone / agonists*,  antagonists & inhibitors*
Humans
Male
Osteoporosis / etiology
Prostatic Neoplasms / drug therapy*
Testosterone / blood
Chemical
Reg. No./Substance:
0/Androgen Antagonists; 33515-09-2/Gonadotropin-Releasing Hormone; 58-22-0/Testosterone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Changing the diagnosis criteria of type 2 diabetes in pregnancy: do the ends justify the means?
Next Document:  Diversity of bone cell activity as a histomorphometric feature of idiopathic osteoporosis in men.